NVCT Nuvectis Pharma Inc

$NVCT completed my partial swap NVCT for GLSI. Both keyed by huge insider ownership and insider buying NVCT - 60% GLSI - 40%

$NVCT fireside chat ultra impressive. CEO explained Novartis trial expanding indications Fabhalta which correlates with opportunity to expand indications lead drug NXP100. No talk around NXP900 mono therapies. Small cash strapped company moving largest market opportunities forward Much bigger opportunities than when I was buying $6 shares. NXP100 oral once daily, lifetime

$NVCT December company will be wrapping up NXP900 1b resistance combo Tagrisso. NVCT my biggest position and believing all 3 drugs will have value in the marketplace. Don't botch this trade, combo can make all other drugs and indications freerolls

$NVCT I'll wait to see if it opens tomorrow around $23 with good volume. Not financial advice :). Info below from my scanner: Buy grade: 6.0 / 10 Confidence: Medium Price (Sep 24, 2026 close): $21.63 Criteria breakdown Longer trend: The stock sits at its 50-day average (~$21.50) and well above its 200-day (~$13) after a climb from the 52-week low of $5.55. It spiked to about $29.27 in late June on the Haisco license news, sold off around the July offering at $20, then traded roughly $20–$25 into September. One-year return is about +250–260%. Valuation: Pre-revenue clinical biotech, so P/E and P/S do not apply. Market cap is about $706–707M. Vendor enterprise value still uses stale June cash ($22M); after the July raise and the $20M Haisco upfront, cash is roughly in the $100M range and EV/cash is closer to about 5.5–6× (estimate from disclosed pieces, not a filed figure). The stock is priced as pipeline optionality, not as an earnings multiple.